Welcome to our dedicated page for Tiziana Life Sciences SEC filings (Ticker: TLSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Tiziana Life Sciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Tiziana Life Sciences's regulatory disclosures and financial reporting.
Tiziana Life Sciences is raising $8.0 million by selling 6,400,000 ordinary shares in a registered direct offering at $1.25 per share to senior management and existing shareholders. For each share purchased, investors receive a warrant to buy one additional share at $1.50 until July 16, 2026, which could bring in up to approximately $9.6 million more, for total potential gross proceeds of about $17.6 million.
The company states that the proceeds will enable completion of its Phase 2 clinical trials in non-active secondary progressive multiple sclerosis (na-SPMS) and multiple system atrophy (MSA) and support topline data readouts. The financing was led by Tiziana’s CEO, who bought 2,400,000 shares, and the Executive Chairman and Founder, who bought 1,600,000 shares through an affiliated entity, increasing their shareholdings significantly.
Tiziana Life Sciences Ltd filed a Form 6-K to share that CEO Ivor Elrifi will deliver a corporate presentation at the 9th Annual Neuroscience Innovation Forum in San Francisco at 2:00 PM PT on January 11, 2026, during J.P. Morgan Healthcare Conference Week. Senior management will also attend for one-on-one meetings with investors, partners, and other stakeholders.
The presentation will focus on Tiziana’s lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody designed to modulate the immune system and reduce microglial activation in neurodegenerative conditions. The company reports that 14 patients with non-active secondary progressive multiple sclerosis in an expanded access program showed improvement or disease stability within 6 months, and intranasal foralumab is also being studied in a Phase 2a randomized, double-blind, placebo-controlled trial.
Tiziana Life Sciences reported that Founder and Executive Chairman Gabriele Cerrone will ring the Nasdaq Closing Bell at the Nasdaq MarketSite in Times Square, New York, on December 17, 2025. The ceremony, held from 3:45 PM to 4:15 PM ET, celebrates the company’s ongoing work on intranasal foralumab, a fully human anti-CD3 monoclonal antibody delivered through the nose. This lead candidate and its nasal delivery approach aim to improve efficacy, safety, and tolerability versus traditional intravenous methods for neurodegenerative and inflammatory diseases such as multiple sclerosis, Alzheimer’s disease, and ALS.
Tiziana Life Sciences LTD reported that the first patient has been dosed with intranasal foralumab in its Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer’s disease. This milestone comes shortly after enrollment began, when the first patient was expected to be dosed imminently. The Phase 2 study is evaluating intranasal foralumab both as a standalone treatment and in combination with FDA-approved anti-amyloid therapies lecanemab (Leqembi) or donanemab in early Alzheimer’s patients.
Tiziana Life Sciences LTD reported that its Chief Executive Officer, Ivor Elrifi, bought 163,400 shares of Tiziana common stock in the open market on December 15, 2025. These purchases increase his total open-market purchased holdings to 357,848 shares.
This move means the company’s top executive has committed more of his own capital to Tiziana’s stock, which some investors view as a sign of confidence in the business. The disclosure is provided in a Form 6-K, with an accompanying press release furnished as Exhibit 99.1.
Tiziana Life Sciences LTD filed a Form 6-K stating that it has withdrawn its proposed public offering of common shares due to market conditions.
The company furnished a press release dated December 15, 2025 as Exhibit 99.1, and specified that this material is being furnished, not deemed filed or automatically incorporated into other securities law filings.
Tiziana Life Sciences Ltd. is conducting a primary best-efforts offering of common shares on Nasdaq to raise cash for its clinical-stage neurology pipeline. ThinkEquity LLC is acting as exclusive placement agent, but is not required to place any minimum number of shares, there is no minimum offering amount and no escrow account, so any funds received will be available to the company immediately.
The company plans to use net proceeds, together with existing cash, mainly to advance its lead candidate foralumab in non-active secondary progressive multiple sclerosis, Alzheimer’s disease and multiple system atrophy, and for working capital, capital spending and general corporate purposes. Because the offering price will be above the company’s net tangible book value, new investors are expected to incur immediate and substantial dilution, and future equity or debt financings could create additional dilution or restrictions. The prospectus also highlights volatility in TLSA’s share price and the likelihood that Tiziana will need further capital even after this offering.
Tiziana Life Sciences LTD reports that enrollment has begun in its Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer’s disease. The study is testing intranasal foralumab, an experimental therapy, both on its own and together with FDA‑approved anti‑amyloid drugs lecanemab or donanemab.
The company plans to dose the first patient next week, indicating the trial is moving from screening into active treatment. Baseline clinical assessments, cognitive testing, TSPO‑PET brain imaging, and fluid biomarker measurements have already been completed for the first participants, laying the groundwork to track how patients respond over time.
Tiziana Life Sciences (TLSA) reported that its Phase 2 clinical trial of intranasal foralumab in patients with amyotrophic lateral sclerosis (ALS) has been accepted into the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS at Mass General Brigham. This places the company’s ALS study within a coordinated clinical research framework focused on the disease. The update is structured as an informational report and does not include financial results or transaction details.
Tiziana Life Sciences (TLSA) furnished a Form 6-K stating its senior leadership will present a corporate overview at the Jefferies London Healthcare Conference. Chief Executive Officer Ivor Elrifi and Chief Operating Officer/Chief Financial Officer Keeren Shah will highlight the company’s innovative pipeline and recent clinical milestones.
The accompanying press release is included as Exhibit 99.1. The information is furnished, not filed, under the Exchange Act and is not incorporated by reference except as specifically stated.